Cetrimonium tosilate

USDailyMed:Ritlecitinib AU:D L04AF08(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only 1-{(2S,5R)-2-methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one 1792180-81-4as salt:2192215-81-7 118115473 9559 DB14924as salt:DBSALT003482 59718512as salt:81368003 2OYE00PC25as salt:EAG4T1459K as salt:D11970 CHEBI:229233 ChEMBL4085457 Interactive image C=CC(=O)‍‍‍‍‍‍​​​‍​​​​​​N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1Key:CBRJPFGIXUFMTM-WDEREUQCSA-NKey:YOZLVAFWYLSRRN-VZXYPILPSA-N Ritlecitinib, sold under the brand nameLitfulo, is amedicationused for the treatment of severealopecia areata(hair loss).Ritlecitinib is akinase inhibitorwhich inhibitsJanus kinase 3andtyrosine kinase. The most common side effects include headache, diarrhea, acne, rashes, eczema, fever, mouth ulcers, dizziness, shingles rash, and abnormal findings in some laboratory test results. Ritlecitinib was approved for medical use in the United States in June 2023,in the European Union in September 2023,and in Canada in November 2023.